Bluebird Bio Says Continuing To Work Expeditiously To Complete Delayed Filings
Bluebird Bio Says Continuing To Work Expeditiously To Complete Delayed Filings
Bluebird Bio表示將繼續儘快完成延遲的申報
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a result, the Company's Annual Report Form 10-K for 2023 and its Q1 2024 Form 10-Q have been delayed.
2024年3月26日，藍鳥宣佈將重報2022年前三個季度和全年以及2023年前三個季度的合併財務報表。因此，公司2023年10-K年度報告表和2024年第一季度10-Q表被推遲。
Consistent with previous updates, the restatement is not expected to impact the Company's cash position or revenue. Sterling will transition to oversee the restatement process upon his start date.
與之前的更新一致，重報預計不會影響公司的現金狀況或收入。斯特林將在開始時過渡到監督重報流程。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。